| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(03)01195-1 |
| P698 | PubMed publication ID | 12965277 |
| P2093 | author name string | Johannes Drach | |
| Sonja Seidl | |||
| Hannes Kaufmann | |||
| P2860 | cites work | Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 | Q28242697 |
| Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma | Q28646235 | ||
| A molecular compendium of genes expressed in multiple myeloma | Q31105650 | ||
| Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients | Q33891633 | ||
| Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. | Q33952275 | ||
| Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells | Q34115598 | ||
| Plasma cells: finding new light at the end of B cell development | Q34450168 | ||
| RANK ligand and osteoprotegerin in myeloma bone disease. | Q34992857 | ||
| Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals | Q35056472 | ||
| Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma | Q35938169 | ||
| Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease | Q36169814 | ||
| Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma | Q37148117 | ||
| Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation | Q38297517 | ||
| Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays | Q38298600 | ||
| Moving disease biology from the lab to the clinic | Q40608454 | ||
| Myeloid cell factor-1 is a critical survival factor for multiple myeloma | Q40655990 | ||
| Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance | Q40695090 | ||
| Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. | Q40797432 | ||
| Multiple myeloma: almost all patients are cytogenetically abnormal | Q41076697 | ||
| The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications | Q43700541 | ||
| Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk | Q43993650 | ||
| Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. | Q44291805 | ||
| Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma | Q44950046 | ||
| Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. | Q52546411 | ||
| A molecular study of the t(4;14) in multiple myeloma. | Q52861322 | ||
| High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis | Q57785902 | ||
| Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma | Q58050885 | ||
| Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease | Q62003041 | ||
| Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance | Q73166114 | ||
| Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hé | Q73396499 | ||
| Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy | Q73586012 | ||
| p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance | Q74064420 | ||
| Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration | Q74129743 | ||
| Hypodiploidy is a major prognostic factor in multiple myeloma | Q74541841 | ||
| Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy | Q74605768 | ||
| Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival | Q74673995 | ||
| Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment | Q77337113 | ||
| Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor | Q78409825 | ||
| Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants | Q78410075 | ||
| In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression | Q78410148 | ||
| Delineation of the minimal region of loss at 13q14 in multiple myeloma | Q78600352 | ||
| P433 | issue | 9 | |
| P921 | main subject | pathophysiology | Q1135939 |
| P304 | page(s) | 557-564 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | New insights into the pathophysiology of multiple myeloma | |
| P478 | volume | 4 |
| Q36331908 | Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. |
| Q36069477 | Angiogenic switch in multiple myeloma. |
| Q35994897 | Angiopoietin-1 and myeloma-induced angiogenesis. |
| Q80477454 | Association between exercise and quality of life in multiple myeloma cancer survivors |
| Q80601795 | Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma |
| Q38062038 | Can we change the disease biology of multiple myeloma? |
| Q39070877 | Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factor-kappa B activation |
| Q61039260 | Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses |
| Q53242836 | Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System. |
| Q36471721 | Common complaints, difficult diagnosis: multiple myeloma |
| Q37351173 | Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. |
| Q39988132 | Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators |
| Q50066396 | Cytogenetic Profiling of Myelomas, Association With Complete Blood Count: Study of 180 Patients |
| Q47340953 | DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies |
| Q80342487 | Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics |
| Q39616662 | Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro |
| Q50330020 | Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance |
| Q37662286 | Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. |
| Q35770297 | High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma |
| Q34517905 | MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. |
| Q24654905 | MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis |
| Q36453354 | Microarray-based understanding of normal and malignant plasma cells |
| Q40195859 | Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. |
| Q39025573 | Molecular cytogenetic aberrations in Tunisian patients with multiple myeloma identified by cIg-FISH in fixed bone marrow cells |
| Q26776386 | Molecular mechanisms in multiple myeloma drug resistance |
| Q38101343 | Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing |
| Q89682913 | Multiple Myeloma: Available Therapies and Causes of Drug Resistance |
| Q55119496 | Multiple Myeloma: Diagnosis and Treatment. |
| Q37004869 | Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases |
| Q37623809 | Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management |
| Q58565204 | Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management |
| Q82510141 | NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm |
| Q38981247 | Next-generation multiple myeloma treatment: a pharmacoeconomic perspective |
| Q40109315 | POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17. |
| Q34788326 | Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study |
| Q33925049 | Stem cells and bone diseases: new tools, new perspective |
| Q37859253 | The bone marrow stroma in hematological neoplasms--a guilty bystander. |
| Q64084639 | Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop |
| Q40291993 | Toll-like receptors mediate proliferation and survival of multiple myeloma cells |
| Q37385547 | Treatment of multiple myeloma in the targeted therapy era. |
| Q35681304 | c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions |
Search more.